GoodRx (NASDAQ:GDRX) Major Shareholder Francisco Partners Iv, L.P. Sells 127,273 Shares of Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $3.44, for a total transaction of $437,819.12. Following the completion of the transaction, the insider owned 643,466 shares of the company’s stock, valued at $2,213,523.04. This trade represents a 16.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $4,536,619.50.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The shares were sold at an average price of $3.46, for a total value of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Trading Up 5.2%

NASDAQ GDRX opened at $3.65 on Thursday. The stock’s 50 day moving average is $3.18 and its 200 day moving average is $2.66. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $1.25 billion, a PE ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.08. The business had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.09 earnings per share. Research analysts forecast that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Several large investors have recently modified their holdings of GDRX. Essential Partners LLC boosted its position in GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after buying an additional 11,295 shares during the period. Meridian Wealth Management LLC purchased a new position in shares of GoodRx during the fourth quarter worth approximately $29,000. SG Americas Securities LLC bought a new stake in shares of GoodRx during the first quarter valued at approximately $29,000. Headlands Technologies LLC bought a new stake in shares of GoodRx during the second quarter valued at approximately $30,000. Finally, Krilogy Financial LLC purchased a new stake in shares of GoodRx in the first quarter valued at approximately $33,000. Institutional investors own 63.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on GDRX. Barclays increased their price objective on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Wells Fargo & Company boosted their price objective on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 7th. TD Cowen increased their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Citigroup raised their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, GoodRx has an average rating of “Hold” and a consensus target price of $4.23.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.